Video Series

Treatment strategies for diabetes should include a comprehensive approach involving multidisciplinary care teams.

Treatment strategies for diabetes should include a comprehensive approach involving multidisciplinary care teams.

A panel of experts discuss the provider, payer, and patient challenges that must be considered with BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma.

Callie Coombs, MD, discusses recent changes you have seen in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL) and provides an overview of the Bruton tyrosine kinase inhibitor landscape for CLL, MCL, and SLL.

Amy McMichael, MD, and Maria Lopes, MD, MS, review the major differences in quality of life, the impact on patients, and the costs and burdens associated with absenteeism or presentism.

Amy McMichael, MD, explores why psoriasis can substantially affect quality of life more severely in some ethnicities more than others.

Paige Nues provides her closing thoughts regarding the treatment management of Rett syndrome.

Paige Nues of the International Rett Syndrome Foundation discusses the complexity of navigating available resources and programs for patients with Rett syndrome, and the critical role of centers of excellence.

Early testing for HoFH may lead to significant improvement in patient prognosis.

Medical experts illustrate an array of characteristics presented in patients with HoFH.

Treatment strategies for patients with lower-risk MDS are examined.

Biosimilar products may be utilized as treatment options in PNH.

A panel of experts discuss the most important goals of therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma and the largest unmet needs in leukemia/lymphoma.

Brian Koffman, MD, and Callie Coombs, MD, provide the prevalence and incidence rates of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL), and describe how the diagnosis and management of CLL/MCL/SLL impacts a patient’s quality of life.

Callie Coombs, MD, and Brian Koffman, MD, provide an overview of chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and explore the key differences between these disease states.

Cardiovascular risk can be significantly impacted by the presence of diabetes.

Experts highlight key factors when considering costs associated with diabetes treatment pathways.

Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.

Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.

Paige Nues of the International Rett Syndrome Foundation explores the broader effect on a patient’s family members and caregivers.

Rett syndrome significantly impacts both patient and family’s quality of life.

Bruce Sherman, MD, FCCP, FACOEM, explores how to improve treatment for psoriasis and education surrounding diagnosing psoriasis for all skin phototypes.

Amy McMichael, MD, and Maria Lopes, MD, MS, review factors to evaluate when starting treatment and how to educate patients on the possible adverse events from that treatment.

Dr Garcia-Manero discusses the effects of TP53 mutation in patients with MDS.

Dr De Castro provides an overview of IV versus oral therapies for patients with PNH.

Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.

A panel of experts discuss the value of clinical pathways in MM disease management.

Adequately treating diabetes demands an array of considerations and therapy strategies.

Dr Handelsman drives a conversation surrounding the management of A1C levels.

Medical experts provide their closing thoughts on the chronic obstructive pulmonary disease treatment landscape.